We reported three cases of NHERF1 intragenic mutations in a panel of breast tumors pre-screened for LOH [15]; notably, all mutations were located at conserved residues of PDZ domains or ERM-interacting domain. This evidence concerns the gene NHERF1 and breast neoplasm.